KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.

Itaru Miura, Kentaro Takai, Shunji Toya, Masaomi Iyo

Int Clin Psychopharmacol 41(3) 176-183

PMID41369302
PMCIDPMC13015809
DOI10.1097/YIC.0000000000000609
发表日期2025-12-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。
摘要

摘要

The aim of this analysis was to examine the impact of treatment with lurasidone on a broad range of symptoms during an acute episode of schizophrenia. In patients with an acute exacerbation of schizophrenia treated with lurasidone in a 6-week, double-blind, placebo-controlled trial, a mixed-effect model for repeated measures was used to analyze weekly change in both the five Marder Factors and the 30 individual items of the Positive and Negative Syndrome Scale (PANSS). Treatment with lurasidone was associated with significant endpoint improvement on all five Marder PANSS factors with effect sizes ranging from 0.22 to 0.44. Significant early (week 2), sustained improvement was observed on four of the five Marder Factors, with significant improvement occurring by week 4 on the Marder Negative Symptom factor. In addition to significant improvement on five out of eight Marder Positive Symptom items, the following non-Positive PANSS items were notable for being especially responsive to lurasidone treatment in terms of significant early improvement and endpoint effect sizes >0.3: anxiety, tension, preoccupation, active social avoidance, and conceptual disorganization. The results of this non-USA study confirm results from previous studies indicating that lurasidone is an effective antipsychotic medication.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition.
非 KM Figure
Fig. 2Mean change over 6 weeks of treatment with lurasidone and placebo for PANSS Marder 5-factors. PANSS, Positive and Negative Syndrome Scale.
非 KM Figure
Fig. 3(a) PANSS individual items: statistical significance of change over time at each weekly assessment. (b) PANSS individual items: statistical significance of change from baseline to week 6. PANSS, Positive and Negative Syndrome Scale.
非 KM Figure